JP2015504870A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504870A5 JP2015504870A5 JP2014547526A JP2014547526A JP2015504870A5 JP 2015504870 A5 JP2015504870 A5 JP 2015504870A5 JP 2014547526 A JP2014547526 A JP 2014547526A JP 2014547526 A JP2014547526 A JP 2014547526A JP 2015504870 A5 JP2015504870 A5 JP 2015504870A5
- Authority
- JP
- Japan
- Prior art keywords
- angiotensin
- disorder
- derivative
- analog
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 claims 1
- 108010021281 angiotensin I (1-7) Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576673P | 2011-12-16 | 2011-12-16 | |
| US61/576,673 | 2011-12-16 | ||
| US201161579936P | 2011-12-23 | 2011-12-23 | |
| US61/579,936 | 2011-12-23 | ||
| PCT/US2012/069930 WO2013090833A1 (en) | 2011-12-16 | 2012-12-14 | Angiotensins for treatment of fibrosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015504870A JP2015504870A (ja) | 2015-02-16 |
| JP2015504870A5 true JP2015504870A5 (enExample) | 2016-02-12 |
Family
ID=48613248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014547526A Pending JP2015504870A (ja) | 2011-12-16 | 2012-12-14 | 線維症を処置するためのアンジオテンシン |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20150057216A1 (enExample) |
| EP (1) | EP2790716A4 (enExample) |
| JP (1) | JP2015504870A (enExample) |
| KR (1) | KR20150028761A (enExample) |
| CN (1) | CN104302305A (enExample) |
| AU (1) | AU2012351939A1 (enExample) |
| BR (1) | BR112014014674A2 (enExample) |
| CA (1) | CA2859573A1 (enExample) |
| WO (1) | WO2013090833A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| JP2016520592A (ja) * | 2013-05-24 | 2016-07-14 | タリックス ファーマシューティカルズ リミテッド | マルファン症候群および関連障害の処置におけるアンジオテンシンペプチド |
| AU2014284496A1 (en) * | 2013-07-03 | 2016-01-21 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method for treating cognitive dysfunction |
| US20170080120A1 (en) * | 2014-05-16 | 2017-03-23 | Ulstrast, Inc. | Phase-shifting formulations |
| US10183055B2 (en) | 2014-07-21 | 2019-01-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications |
| CN106535920B (zh) | 2014-07-21 | 2020-10-30 | 代表亚利桑那大学的亚利桑那校董会 | Ang-(1-7)衍生物寡肽及其使用和生产方法 |
| CA2963945C (en) | 2014-10-07 | 2023-01-10 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| MA41120A (fr) * | 2014-12-02 | 2017-10-10 | Afimmune Ltd | Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci |
| WO2017015720A1 (en) | 2015-07-30 | 2017-02-02 | Monash University | Fibrotic treatment |
| US10960045B2 (en) * | 2015-10-14 | 2021-03-30 | Constant Therapeutics Llc | Methods and compositions for the treatment of epidermolysis bullosa |
| WO2017218623A1 (en) * | 2016-06-14 | 2017-12-21 | Tarix Orphan Llc | Methods and compositions for the treatment of epidermolysis bullosa |
| CN111163793A (zh) * | 2017-07-17 | 2020-05-15 | 莫纳什大学 | 血管紧张素受体激动剂及其用途 |
| GB201913603D0 (en) | 2019-09-20 | 2019-11-06 | Vicore Pharma Ab | New compounds |
| CN115297867A (zh) * | 2020-02-20 | 2022-11-04 | 理筱龙 | 人参皂甙m1作为血管收缩素调节酶的调节剂及其在治疗包括冠状病毒引起的症状的疾病或病征的用途 |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
| EP4085896A1 (en) * | 2021-05-04 | 2022-11-09 | CU-Pharmaceuticals UG | Pharmaceutical angiotensin-(1-7) compositions in the treatment of (sars)-cov- or (sars)-cov-2-infection related diseases |
| EP4085921A1 (en) * | 2021-05-04 | 2022-11-09 | CU-Pharmaceuticals UG | Angiotensin-(1-7) in the treatment of sars-cov related diseases |
| KR20240148359A (ko) | 2022-02-10 | 2024-10-11 | 바이코어 파마 아베 | 특발성 폐섬유증 치료를 위한 불록시부티드의 용도 |
| GB202201723D0 (en) | 2022-02-10 | 2022-03-30 | Vicore Pharma Ab | New use |
| EP4775589A1 (en) * | 2023-09-08 | 2026-07-15 | Pontificia Universidad Católica de Chile | Pharmaceutical composition comprising a peptide or a combination of peptides agonistic to the mas, at1 and at2 receptors |
| KR102743940B1 (ko) | 2023-10-06 | 2024-12-19 | 엠브릭스 주식회사 | 안지오텐신 전환효소 2 및 Fc 절편을 포함하는 나노디스크 및 이의 용도 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE268782T1 (de) * | 1997-12-12 | 2004-06-15 | Univ Southern California | Zusammensetzungen zur wundheilung |
| YU78601A (sh) * | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
| US7064127B2 (en) * | 2003-12-19 | 2006-06-20 | Mount Sinai School Of Medicine Of New York University | Treatment of hepatic fibrosis with imatinib mesylate |
| ES2393455T3 (es) * | 2008-09-12 | 2012-12-21 | Charité-Universitátsmedizin Berlin (Charité) | Uso de un agonista del receptor Ang-(1-7) en lesiones pulmonares agudas |
-
2012
- 2012-12-14 JP JP2014547526A patent/JP2015504870A/ja active Pending
- 2012-12-14 US US14/365,565 patent/US20150057216A1/en not_active Abandoned
- 2012-12-14 CN CN201280069856.3A patent/CN104302305A/zh active Pending
- 2012-12-14 BR BR112014014674A patent/BR112014014674A2/pt not_active Application Discontinuation
- 2012-12-14 EP EP12857486.0A patent/EP2790716A4/en not_active Withdrawn
- 2012-12-14 CA CA2859573A patent/CA2859573A1/en not_active Abandoned
- 2012-12-14 AU AU2012351939A patent/AU2012351939A1/en not_active Abandoned
- 2012-12-14 KR KR20147019878A patent/KR20150028761A/ko not_active Withdrawn
- 2012-12-14 WO PCT/US2012/069930 patent/WO2013090833A1/en not_active Ceased
-
2015
- 2015-11-23 US US14/948,985 patent/US20160074466A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015503422A5 (enExample) | ||
| JP2014530840A5 (enExample) | ||
| JP2015528502A5 (enExample) | ||
| JP2012143233A5 (enExample) | ||
| JP2013525942A5 (enExample) | ||
| PT2729151T (pt) | Composição farmacêutica, métodos de tratamento e suas utilizações | |
| JP2014520248A5 (enExample) | ||
| BR112014004181A2 (pt) | composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia | |
| JP2011170856A5 (enExample) | ||
| HUE045629T2 (hu) | Készítmények, alkalmazások és eljárások anyagcsere rendellenességek és betegségek kezelésére | |
| LT3470063T (lt) | Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui | |
| LT3251678T (lt) | Benzoksaborolo dariniai, skirti bakterinių infekcijų gydymui | |
| JP2013514381A5 (enExample) | ||
| JP2016515522A5 (enExample) | ||
| BRPI0917567A2 (pt) | tratamento de doença respiratória | |
| EP2799540A4 (en) | HUMAN ARGINASE AND PEGYLATED HUMAN ARGINASE AND USE THEREOF | |
| JP2015525757A5 (enExample) | ||
| LT3292875T (lt) | Kompozicijos ir būdai, skirti ligų gydymui | |
| JP2014526140A5 (enExample) | ||
| ZA201402907B (en) | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies | |
| BRPI0906606A2 (pt) | Tratamento terapêutico para condições do pulmão. | |
| DK2931296T3 (da) | Sygdomsbehandling, der involverer mucin | |
| WO2012100043A3 (en) | Controlled release oral pharmaceutical dosage forms comprising mgbg | |
| LTPA2020511I1 (lt) | Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui | |
| HUE041883T2 (hu) | Samidorphan (ALKS 33) és buprenorfin kombináció, depressziós zavarok kezelésére |